Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-183C antagomir
- Development stage
- Preclinical
- Lead developer
- Virginia Tech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
miR-183C antagomir is a synthetic antisense oligonucleotide designed to inhibit the miR-183-96-182 (miR-183C) microRNA cluster. This cluster is highly conserved and has been found to be significantly upregulated in the splenic cells of murine models of systemic lupus erythematosus (SLE). By antagonizing these microRNAs, the agent increases the expression of forkhead box O1 (Foxo1), a direct target of the cluster, which in turn suppresses the production of inflammatory cytokines such as IFN-γ and IL-6. Preclinical research in B6-lpr mice has demonstrated that inhibition or depletion of miR-183C reduces anti-dsDNA autoantibody production and IgG deposition in the kidneys, suggesting its potential as a therapeutic strategy for autoimmune diseases like SLE.
- Other names
- miR-183-96-182 antagomirmiR183-96-182 antagomirmiR 183-96-182 antagomirantagomir-183Cantagomir183Cantagomir 183CmiR-183 cluster antagomirmiR183 cluster antagomirmiR 183 cluster antagomir
02
Targets
miR-183 (microRNA-183)miR-96 (MicroRNA-96)
Beyond the preview
Go deeper on miR-183C antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-183C antagomir.